Athernal Bio

- 02/10/2025
- Unknown
- $4,718,630
Developing targeted immunotherapies to treat high-risk clonal haematopoiesis (CH)—the precursor to blood cancers—so we can stop cancer before it starts.
- Industry Biotechnology Research
- Website https://www.athernalbio.com/
- LinkedIn https://www.linkedin.com/company/athernal-bio/
Related People
Colin FreundFounder

C-level executive with experience in both private and public biotechnology companies, with 18 years' experience leading multinational teams that drive revenue generation and corporate value creation: company leadership (including venture fundraising); strategic planning, business/corporate development and M&A ($500M+ in multiple licensing/M&A transactions); corporate restructuring; alliance management; commercial development and product launch preparation; supply chain optimization; organizational development; investor relations/fundraising; and business interface on regulatory strategy in the USA, Europe and Asia.